Ahlim Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ahlim Lee has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Hyun Yang
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
56 shared publications - Si Hyun Bae
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
55 shared publications - Chang Wook Kim
The Catholic University Liver Research Center, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea
54 shared publications - Hae Lim Lee
Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
54 shared publications - Heechul Nam
The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
54 shared publications - Jeong Won Jang
The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
54 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 2925-2937
Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction‐Associated Steatotic Liver Disease Across Divergent Screening Goals
Background: Although numerous noninvasive indices have been proposed to assess significant fibrosis (SF), none have been validated specifically in young adults with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study evaluated their performance in younger patients across two cohorts with distinct screening goals. Methods: We retrospectively analyzed two MASLD cohorts: a primary care (PC) cohort ( n = 972) and a tertiary care (TC) cohort ( n = 342). SF was defined as liver stiffness ≥ 7.0 kPa on vibration‐controlled transient elastography. The diagnostic performance of emerging indices—fibrosis‐8 index, steatosis‐associated fibrosis estimator, metabolic‐associated fibrosis score‐5—was compared with traditional scores—fibrosis‐4 index, aspartate aminotransferase‐to‐platelet ratio index, and nonalcoholic fatty liver disease fibrosis score. Results: Across both settings, emerging indices consistently outperformed traditional scores for SF discrimination. The areas under the receiver operating characteristic curves were higher for the emerging indices than for the traditional indices in both cohorts. Decision curve analyses demonstrated that emerging indices provided greater net clinical benefit and larger reductions in unnecessary procedures, with thresholds differing by setting such that lower thresholds favored referral in the PC cohort, whereas higher thresholds were more appropriate for biopsy decisions in the TC cohort. Conventional cutoffs widely used in practice demonstrated limited sensitivity in this population, suggesting that refinement may be required. Conclusions: Traditional noninvasive fibrosis indices showed limited performance in young adults with MASLD, whereas emerging indices appeared more suitable for achieving the screening goals of referral in PC and biopsy decision‐making in TC.
- 11 August 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (9) , 2925-2937
Open AccessEmerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction‐Associated Steatotic Liver Disease Across Divergent Screening Goals
Background: Although numerous noninvasive indices have been proposed to assess significant fibrosis (SF), none have been validated specifically in young adults with metabolic dysfunction‐associated steatotic liver disease (MASLD). This study evaluated their performance in younger patients across two cohorts with distinct screening goals. Methods: We retrospectively analyzed two MASLD cohorts: a primary care (PC) cohort ( n = 972) and a tertiary care (TC) cohort ( n = 342). SF was defined as liver stiffness ≥ 7.0 kPa on vibration‐controlled transient elastography. The diagnostic performance of emerging indices—fibrosis‐8 index, steatosis‐associated fibrosis estimator, metabolic‐associated fibrosis score‐5—was compared with traditional scores—fibrosis‐4 index, aspartate aminotransferase‐to‐platelet ratio index, and nonalcoholic fatty liver disease fibrosis score. Results: Across both settings, emerging indices consistently outperformed traditional scores for SF discrimination. The areas under the receiver operating characteristic curves were higher for the emerging indices than for the traditional indices in both cohorts. Decision curve analyses demonstrated that emerging indices provided greater net clinical benefit and larger reductions in unnecessary procedures, with thresholds differing by setting such that lower thresholds favored referral in the PC cohort, whereas higher thresholds were more appropriate for biopsy decisions in the TC cohort. Conventional cutoffs widely used in practice demonstrated limited sensitivity in this population, suggesting that refinement may be required. Conclusions: Traditional noninvasive fibrosis indices showed limited performance in young adults with MASLD, whereas emerging indices appeared more suitable for achieving the screening goals of referral in PC and biopsy decision‐making in TC.
- 14 January 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (2) , e70134
Challenges of an EMR‐Based Hospital Alert Program for Micro‐Elimination of Hepatitis C in Tertiary Referral Hospitals
Despite advances in hepatitis C virus (HCV) treatments, diagnostic gaps and linkage‐to‐care hinder elimination efforts. We evaluated an electronic medical record (EMR)‐based automated alert system to improve HCV care at tertiary referral centers. We have screened 1,303,578 patients who were tested for anti‐HCV, and analyzed 8291 patients positive for anti‐HCV antibody (Ab) across four tertiary hospitals between July 2009 and December 2023. The EMR alert system, implemented in June 2021, identified patients with positive anti‐HCV antibody results who had not undergone HCV ribonucleic acid (RNA) testing. We compared HCV RNA testing rates, linkage‐to‐care and time intervals between testing before and after system implementation. The HCV RNA test prescription rate increased from 60.5% in the pre‐alert period to 66.9% in the post‐alert period. In non‐hepatology departments, the prescription rate increased from 47.1% to 60.5%. The interval between HCV Ab positivity to HCV RNA test prescription in patients without initial HCV RNA order decreased significantly from 1208.9 to 244.5 days. Among 732 previously HCV RNA untested patients who were followed up after alert implementation, 43.4% received HCV RNA testing, leading to 62 new HCV diagnoses. The referral rate to hepatology departments remained stable (83.3% pre‐alert vs. 80.9% post‐alert). In conclusion, implementation of an EMR‐based alert system effectively improved HCV diagnostic rates and reduced testing delays, particularly in non‐hepatology departments. This system represents a promising strategy for hospital‐based HCV micro‐elimination, but additional interventions might be needed to achieve optimal testing rates and linkage‐to‐care.
- 14 January 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (2) , e70134
Challenges of an EMR‐Based Hospital Alert Program for Micro‐Elimination of Hepatitis C in Tertiary Referral Hospitals
Despite advances in hepatitis C virus (HCV) treatments, diagnostic gaps and linkage‐to‐care hinder elimination efforts. We evaluated an electronic medical record (EMR)‐based automated alert system to improve HCV care at tertiary referral centers. We have screened 1,303,578 patients who were tested for anti‐HCV, and analyzed 8291 patients positive for anti‐HCV antibody (Ab) across four tertiary hospitals between July 2009 and December 2023. The EMR alert system, implemented in June 2021, identified patients with positive anti‐HCV antibody results who had not undergone HCV ribonucleic acid (RNA) testing. We compared HCV RNA testing rates, linkage‐to‐care and time intervals between testing before and after system implementation. The HCV RNA test prescription rate increased from 60.5% in the pre‐alert period to 66.9% in the post‐alert period. In non‐hepatology departments, the prescription rate increased from 47.1% to 60.5%. The interval between HCV Ab positivity to HCV RNA test prescription in patients without initial HCV RNA order decreased significantly from 1208.9 to 244.5 days. Among 732 previously HCV RNA untested patients who were followed up after alert implementation, 43.4% received HCV RNA testing, leading to 62 new HCV diagnoses. The referral rate to hepatology departments remained stable (83.3% pre‐alert vs. 80.9% post‐alert). In conclusion, implementation of an EMR‐based alert system effectively improved HCV diagnostic rates and reduced testing delays, particularly in non‐hepatology departments. This system represents a promising strategy for hospital‐based HCV micro‐elimination, but additional interventions might be needed to achieve optimal testing rates and linkage‐to‐care.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data1 from Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
Supplementary Figures Figure S1. Risk analysis of overall survival based on ALBI score. (A) Restricted cubic spline curve showing the association between ALBI score and hazard ratio for overall survival in patients with Child-Pugh score 7. (B) Kaplan–Meier survival analysis comparing overall survival between patients with Child-Pugh score 7 stratified by ALBI score (cut-off: −1.9). Figure S2 Restricted mean survival time analysis in patients with Child-Pugh score 6 and 7. (A) Comparison of RMST between patients with Child-Pugh score 6 and favorable Child-Pugh score 7. (B) Comparison of RMST between patients with Child-Pugh score 6 and unfavorable Child-Pugh score 7. (C) Comparison of RMST between favorable and unfavorable Child-Pugh score 7 groups. Supplementary Tables Table S1. Factors associated with survival outcomes Table S2. Documented adverse events in patients with Child-Pugh score 6 and 7.
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data1 from Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
Supplementary Figures Figure S1. Risk analysis of overall survival based on ALBI score. (A) Restricted cubic spline curve showing the association between ALBI score and hazard ratio for overall survival in patients with Child-Pugh score 7. (B) Kaplan–Meier survival analysis comparing overall survival between patients with Child-Pugh score 7 stratified by ALBI score (cut-off: −1.9). Figure S2 Restricted mean survival time analysis in patients with Child-Pugh score 6 and 7. (A) Comparison of RMST between patients with Child-Pugh score 6 and favorable Child-Pugh score 7. (B) Comparison of RMST between patients with Child-Pugh score 6 and unfavorable Child-Pugh score 7. (C) Comparison of RMST between favorable and unfavorable Child-Pugh score 7 groups. Supplementary Tables Table S1. Factors associated with survival outcomes Table S2. Documented adverse events in patients with Child-Pugh score 6 and 7.
- Open Access
- 23 May 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (20) , 4323-4332
Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
Purpose: Given the limited data on the effectiveness of atezolizumab plus bevacizumab (Ate/Bev) in patients with hepatocellular carcinoma with a Child-Pugh score (CPS) of 7, this study aims to evaluate the treatment’s efficacy in this population and identify specific CPS 7 subgroups that may benefit from it. Experimental Design: This study included patients with advanced hepatocellular carcinoma who received Ate/Bev as first-line therapy between September 2020 and December 2023 at seven university hospitals. The primary outcome was overall survival (OS), whereas secondary outcomes included progression-free survival (PFS) and treatment response. Results: Among the 374 included patients, those with CPS 5 (n = 169) demonstrated the highest OS and PFS, followed by patients with CPS 6 (n = 105) and CPS 7 (n = 100; P < 0.05). For the variables comprising CPS, the HR for OS increased with elevated total bilirubin levels and was lower in patients with mild ascites (P < 0.05). The HR for OS tended to increase as albumin levels dropped to 2.8 g/dL. Based on these findings, patients with CPS 7 were further classified into two subgroups: favorable (total bilirubin <2 mg/dL, 3.5 ≥ albumin ≥ 2.8 g/dL, mild ascites, and absence of hepatic encephalopathy) and unfavorable (other CPS 7). Compared with patients with CPS 6, those in the favorable CPS 7 group exhibited comparable OS and PFS, whereas patients with unfavorable CPS 7 had significantly lower OS and PFS (P < 0.05). These findings were consistently observed in the multivariate analysis. Conclusions: This study suggests that Ate/Bev treatment can be effective in a subset of patients with CPS 7, highlighting the potential to broaden treatment eligibility for this population. See related commentary by Li and Kelley, p. 4220
- 23 May 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (20) , 4323-4332
Open AccessSubset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
Purpose: Given the limited data on the effectiveness of atezolizumab plus bevacizumab (Ate/Bev) in patients with hepatocellular carcinoma with a Child-Pugh score (CPS) of 7, this study aims to evaluate the treatment’s efficacy in this population and identify specific CPS 7 subgroups that may benefit from it. Experimental Design: This study included patients with advanced hepatocellular carcinoma who received Ate/Bev as first-line therapy between September 2020 and December 2023 at seven university hospitals. The primary outcome was overall survival (OS), whereas secondary outcomes included progression-free survival (PFS) and treatment response. Results: Among the 374 included patients, those with CPS 5 (n = 169) demonstrated the highest OS and PFS, followed by patients with CPS 6 (n = 105) and CPS 7 (n = 100; P < 0.05). For the variables comprising CPS, the HR for OS increased with elevated total bilirubin levels and was lower in patients with mild ascites (P < 0.05). The HR for OS tended to increase as albumin levels dropped to 2.8 g/dL. Based on these findings, patients with CPS 7 were further classified into two subgroups: favorable (total bilirubin <2 mg/dL, 3.5 ≥ albumin ≥ 2.8 g/dL, mild ascites, and absence of hepatic encephalopathy) and unfavorable (other CPS 7). Compared with patients with CPS 6, those in the favorable CPS 7 group exhibited comparable OS and PFS, whereas patients with unfavorable CPS 7 had significantly lower OS and PFS (P < 0.05). These findings were consistently observed in the multivariate analysis. Conclusions: This study suggests that Ate/Bev treatment can be effective in a subset of patients with CPS 7, highlighting the potential to broaden treatment eligibility for this population. See related commentary by Li and Kelley, p. 4220
- Open Access
- 11 April 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (3) , 427-437
Predicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis
Jihye Lim, Ji Hoon Kim, Ahlim Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Heechul Nam, Hae Lim Lee, Do Seon Song, Sung Won Lee, Hee Yeon Kim, Jung Hyun Kwon, Chang Wook Kim, U Im Chang, Soon Woo Nam, Seok-Hwan Kim, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Myeong Jun Song. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl240584
- 11 April 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (3) , 427-437
Open AccessPredicting Mortality and Cirrhosis-Related Complications with MELD3.0: A Multicenter Cohort Analysis
Jihye Lim, Ji Hoon Kim, Ahlim Lee, Ji Won Han, Soon Kyu Lee, Hyun Yang, Heechul Nam, Hae Lim Lee, Do Seon Song, Sung Won Lee, Hee Yeon Kim, Jung Hyun Kwon, Chang Wook Kim, U Im Chang, Soon Woo Nam, Seok-Hwan Kim, Pil Soo Sung, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Myeong Jun Song. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl240584
- Open Access
- 18 July 2024
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (5) , 877-887
Effect of Biliary Drainage on the Prognosis of Patients with Hepatocellular Carcinoma and Bile Duct Invasion
Keungmo Yang, Hyun Yang, Chang Wook Kim, Hee Chul Nam, Ji Hoon Kim, Ahlim Lee, U Im Chang, Jin Mo Yang, Hae Lim Lee, Jung Hyun Kwon, Soon Woo Nam, Soon Kyu Lee, Pil Soo Sung, Ji Won Han, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hee Yeon Kim. Gut and Liver 2024;18:877-87. https://doi.org/10.5009/gnl240032
- 18 July 2024
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 18 (5) , 877-887
Open AccessEffect of Biliary Drainage on the Prognosis of Patients with Hepatocellular Carcinoma and Bile Duct Invasion
Keungmo Yang, Hyun Yang, Chang Wook Kim, Hee Chul Nam, Ji Hoon Kim, Ahlim Lee, U Im Chang, Jin Mo Yang, Hae Lim Lee, Jung Hyun Kwon, Soon Woo Nam, Soon Kyu Lee, Pil Soo Sung, Ji Won Han, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Hee Yeon Kim. Gut and Liver 2024;18:877-87. https://doi.org/10.5009/gnl240032
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Kaplan–Meier curves examining the survival differences of three representative modalities in each risk subgroup by CLAM-C.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Kaplan–Meier curves examining the survival differences of three representative modalities in each risk subgroup by CLAM-C.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Comparison of model performances for predicting 6-month, 12-month, and 24-month survival
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Comparison of model performances for predicting 6-month, 12-month, and 24-month survival
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Unsupervised clustering according to the 12-month mortality predicted by XGBoost and the actual observed 12-month death was performed.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Unsupervised clustering according to the 12-month mortality predicted by XGBoost and the actual observed 12-month death was performed.
- Open Access
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Performances for the prediction of 12-month survival of each XGBoost model according to the sex.
- 1 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Machine Learning Algorithm Facilitates Prognosis Prediction and Treatment Selection for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma
Performances for the prediction of 12-month survival of each XGBoost model according to the sex.